Last reviewed · How we verify
Zanubrutinib Oral Capsule
Zanubrutinib Oral Capsule is a Small molecule drug developed by Stichting Hemato-Oncologie voor Volwassenen Nederland. It is currently in Phase 2 development. Also known as: Brukinsa, Zanubrutinib (BGB-3111).
At a glance
| Generic name | Zanubrutinib Oral Capsule |
|---|---|
| Also known as | Brukinsa, Zanubrutinib (BGB-3111) |
| Sponsor | Stichting Hemato-Oncologie voor Volwassenen Nederland |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies (PHASE1)
- Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (PHASE2)
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (PHASE3)
- A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (PHASE3)
- Zanubrutinib in Primary Cold Agglutinin Disease (PHASE2)
- A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy (PHASE2, PHASE3)
- Zanubritnib and Anti-MAG Neuropathy (PHASE2)
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zanubrutinib Oral Capsule CI brief — competitive landscape report
- Zanubrutinib Oral Capsule updates RSS · CI watch RSS
- Stichting Hemato-Oncologie voor Volwassenen Nederland portfolio CI
Frequently asked questions about Zanubrutinib Oral Capsule
What is Zanubrutinib Oral Capsule?
Zanubrutinib Oral Capsule is a Small molecule drug developed by Stichting Hemato-Oncologie voor Volwassenen Nederland.
Who makes Zanubrutinib Oral Capsule?
Zanubrutinib Oral Capsule is developed by Stichting Hemato-Oncologie voor Volwassenen Nederland (see full Stichting Hemato-Oncologie voor Volwassenen Nederland pipeline at /company/stichting-hemato-oncologie-voor-volwassenen-nederland).
Is Zanubrutinib Oral Capsule also known as anything else?
Zanubrutinib Oral Capsule is also known as Brukinsa, Zanubrutinib (BGB-3111).
What development phase is Zanubrutinib Oral Capsule in?
Zanubrutinib Oral Capsule is in Phase 2.
Related
- Manufacturer: Stichting Hemato-Oncologie voor Volwassenen Nederland — full pipeline
- Also known as: Brukinsa, Zanubrutinib (BGB-3111)
- Compare: Zanubrutinib Oral Capsule vs similar drugs
- Pricing: Zanubrutinib Oral Capsule cost, discount & access